| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:35 UTC |
|---|
| HMDB ID | HMDB0014334 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Bortezomib |
|---|
| Description | Bortezomib, also known as velcade or PS 341, belongs to the class of organic compounds known as phenylalanine and derivatives. Phenylalanine and derivatives are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. Bortezomib is a drug which is used for treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies. Bortezomib is an extremely weak basic (essentially neutral) compound (based on its pKa). |
|---|
| Structure | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide | ChEBI | | PS 341 | ChEBI | | PS-341 | ChEBI | | Velcade | ChEBI | | 341, PS | HMDB | | LDP 341 | HMDB | | LDP-341 | HMDB |
|
|---|
| Chemical Formula | C19H25BN4O4 |
|---|
| Average Molecular Weight | 384.237 |
|---|
| Monoisotopic Molecular Weight | 384.196885774 |
|---|
| IUPAC Name | [(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid |
|---|
| Traditional Name | bortezomib |
|---|
| CAS Registry Number | 179324-69-7 |
|---|
| SMILES | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O |
|---|
| InChI Identifier | InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 |
|---|
| InChI Key | GXJABQQUPOEUTA-RDJZCZTQSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylalanine and derivatives. Phenylalanine and derivatives are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Phenylalanine and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenylalanine or derivatives
- N-acyl-alpha amino acid or derivatives
- Alpha-amino acid amide
- Amphetamine or derivatives
- Pyrazine carboxylic acid or derivatives
- Pyrazinecarboxamide
- 2-heteroaryl carboxamide
- Monocyclic benzene moiety
- Fatty amide
- Pyrazine
- Benzenoid
- Fatty acyl
- Heteroaromatic compound
- Boronic acid derivative
- Boronic acid
- Carboxamide group
- Secondary carboxylic acid amide
- Azacycle
- Organic metalloid salt
- Organoheterocyclic compound
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organoboron compound
- Organopnictogen compound
- Alkylborane
- Carbonyl group
- Organic oxygen compound
- Organic nitrogen compound
- Monoalkylborane
- Organic salt
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.053 g/L | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 28.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2465.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 262.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 186.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 169.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 144.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 493.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 564.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 69.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1181.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 487.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1347.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 312.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 390.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 167.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 154.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Bortezomib,1TMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)[Si](C)(C)C | 2901.8 | Semi standard non polar | 33892256 | | Bortezomib,1TMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)[Si](C)(C)C | 2732.2 | Standard non polar | 33892256 | | Bortezomib,1TMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)[Si](C)(C)C | 4729.1 | Standard polar | 33892256 | | Bortezomib,1TMS,isomer #2 | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C)B(O)O | 2934.1 | Semi standard non polar | 33892256 | | Bortezomib,1TMS,isomer #2 | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C)B(O)O | 2598.7 | Standard non polar | 33892256 | | Bortezomib,1TMS,isomer #2 | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C)B(O)O | 4643.1 | Standard polar | 33892256 | | Bortezomib,2TMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C)[Si](C)(C)C | 2901.7 | Semi standard non polar | 33892256 | | Bortezomib,2TMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C)[Si](C)(C)C | 2737.0 | Standard non polar | 33892256 | | Bortezomib,2TMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C)[Si](C)(C)C | 4311.6 | Standard polar | 33892256 | | Bortezomib,1TBDMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C | 3121.2 | Semi standard non polar | 33892256 | | Bortezomib,1TBDMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C | 2898.7 | Standard non polar | 33892256 | | Bortezomib,1TBDMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C | 4714.1 | Standard polar | 33892256 | | Bortezomib,1TBDMS,isomer #2 | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C)B(O)O | 3141.5 | Semi standard non polar | 33892256 | | Bortezomib,1TBDMS,isomer #2 | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C)B(O)O | 2783.1 | Standard non polar | 33892256 | | Bortezomib,1TBDMS,isomer #2 | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C)B(O)O | 4615.6 | Standard polar | 33892256 | | Bortezomib,2TBDMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3287.2 | Semi standard non polar | 33892256 | | Bortezomib,2TBDMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3066.9 | Standard non polar | 33892256 | | Bortezomib,2TBDMS,isomer #1 | CC(C)C[C@@H](B(O)O)N(C(=O)[C@H](CC1=CC=CC=C1)N(C(=O)C1=CN=CC=N1)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4352.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Bortezomib GC-MS (Non-derivatized) - 70eV, Positive | splash10-002e-9242000000-9fa602d07e0566dc1738 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Bortezomib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Bortezomib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Bortezomib LC-ESI-qTof , Positive-QTOF | splash10-0a4i-0035900000-122163b342b985220f63 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Bortezomib LC-ESI-qTof , Positive-QTOF | splash10-016r-1397000000-e168634cfe7e1453d742 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Bortezomib , positive-QTOF | splash10-0a4i-0035900000-122163b342b985220f63 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Bortezomib , positive-QTOF | splash10-016r-1397000000-e168634cfe7e1453d742 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 10V, Positive-QTOF | splash10-0040-0945000000-717d35ff034d0823a60b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 20V, Positive-QTOF | splash10-040r-2920000000-7cf2f714cdc618ca8e8c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 40V, Positive-QTOF | splash10-0a59-9500000000-a64c45db287441805ffc | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 10V, Negative-QTOF | splash10-00lr-4369000000-54da8c6f6ac19bc3a537 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 20V, Negative-QTOF | splash10-0a7i-7696000000-a8904f81583ba4b00fd9 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 40V, Negative-QTOF | splash10-00b9-9830000000-fb072cbf98c79ced110d | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 10V, Positive-QTOF | splash10-000i-0019000000-738c7318d1c90ad3d40e | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 20V, Positive-QTOF | splash10-002r-2497000000-05ce46c969a07d400170 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 40V, Positive-QTOF | splash10-0a4i-2910000000-b1c62abf177f3ec176c5 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 10V, Negative-QTOF | splash10-00kr-0009000000-f57a7486c4cab88316bf | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 20V, Negative-QTOF | splash10-0006-9012000000-f47b8deb96b3fec82f1d | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bortezomib 40V, Negative-QTOF | splash10-0006-9100000000-8c4defe85755665f03f3 | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. [PubMed:14695130 ]
- Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-11. [PubMed:15199612 ]
- Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [PubMed:15953001 ]
- Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007 Apr;21(4):838-42. Epub 2007 Feb 1. [PubMed:17268529 ]
|
|---|